Annette Molinaro

List of Publications by Year
in descending order

37 papers	440 citations	1163117 8 h-index	1058476 14 g-index
37 all docs	37 docs citations	37 times ranked	766 citing authors

#	Article	IF	Citations
1	Derivation and validation of a clinical prediction rule for uncomplicated ureteral stone--the STONE score: retrospective and prospective observational cohort studies. BMJ, The, 2014, 348, g2191-g2191.	6.0	119
2	A pilot precision medicine trial for children with diffuse intrinsic pontine glioma—PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. International Journal of Cancer, 2019, 145, 1889-1901.	5.1	84
3	STONE PLUS: Evaluation of Emergency Department Patients With Suspected Renal Colic, Using a Clinical Prediction Tool Combined With Point-of-Care Limited Ultrasonography. Annals of Emergency Medicine, 2016, 67, 439-448.	0.6	67
4	Prevalence and Clinical Importance of Alternative Causes of Symptoms Using a Renal Colic Computed Tomography Protocol in Patients With Flank or Back Pain and Absence of Pyuria. Academic Emergency Medicine, 2013, 20, 470-478.	1.8	53
5	Ureteral Stones: Implementation of a Reduced-Dose CT Protocol in Patients in the Emergency Department with Moderate to High Likelihood of Calculi on the Basis of STONE Score. Radiology, 2016, 280, 743-751.	7.3	29
6	Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. Journal of Neuro-Oncology, 2016, 130, 171-179.	2.9	24
7	Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 125-131.	0.8	24
8	Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. Journal of Neuro-Oncology, 2017, 132, 171-179.	2.9	13
9	Smoking Is an Independent Risk Factor for 90-Day Readmission and Reoperation Following Posterior Cervical Decompression and Fusion. Neurosurgery, 2021, 88, 1088-1094.	1.1	10
10	A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. Journal of Clinical Neuroscience, 2015, 22, 155-160.	1.5	8
11	The nuts and bolts of hypothesis testing. Neuro-Oncology Practice, 2016, 3, 139-144.	1.6	3
12	PATH-09. CLINICAL CHARACTERISTICS OF ADULTS WITH H3 K27M-MUTANT GLIOMAS AT UCSF. Neuro-Oncology, 2018, 20, vi159-vi160.	1.2	2
13	Socioeconomic factors associated with pediatric moyamoya disease hospitalizations: a nationwide cross-sectional study. Journal of Neurosurgery: Pediatrics, 2022, 29, 602-611.	1.3	2
14	Factor analysis for survival time prediction with informative censoring and diverse covariates. Statistics in Medicine, 2019, 38, 3719-3732.	1.6	1
15	DDRE-12. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG). Neuro-Oncology, 2020, 22, ii63-ii64.	1.2	1
16	GENE-55. CONSTITUTIONAL MUTATIONS IN TERT AND MENINGIOMA RISK. Neuro-Oncology, 2017, 19, vi104-vi105.	1.2	0
17	SURG-02. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi250-vi250.	1.2	0
18	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. Neuro-Oncology, 2018, 20, vi159-vi159.	1.2	0

#	Article	IF	Citations
19	EPID-12. USING GERMLINE VARIANTS TO PREDICT GLIOMA RISK AND IDENTIFY GLIOMA SUBTYPE PRE-OPERATIVELY. Neuro-Oncology, 2018, 20, vi82-vi82.	1.2	0
20	PATH-05. IMPLEMENTATION OF A TARGETED NEXT-GENERATION SEQUENCING PANEL FOR THE DIAGNOSIS AND PRECISION MEDICINE TREATMENT OF ADULT PATIENTS WITH WHO GRADE IV DIFFUSE GLIOMAS. Neuro-Oncology, 2018, 20, vi158-vi159.	1.2	0
21	IMMU-07. IMMUNE PROFILES IN THE SAN FRANCISCO ADULT GLIOMA STUDY (AGS) USING IMMUNOMETHYLOMICS. Neuro-Oncology, 2018, 20, vi122-vi122.	1.2	0
22	NIMG-11. DIFFERENTIATING TREATMENT-INDUCED EFFECTS FROM TRUE RECURRENT HIGH GRADE GLIOMA USING MULTIPARAMETRIC MRI TECHNIQUES. Neuro-Oncology, 2018, 20, vi177-vi178.	1.2	0
23	PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS. Neuro-Oncology, 2018, 20, vi164-vi165.	1.2	0
24	GENE-47. A 3D ATLAS TO EVALUATE THE SPATIAL PATTERNING OF GENETIC ALTERATIONS AND TUMOR CELL STATES IN GLIOMA. Neuro-Oncology, 2019, 21, vi107-vi108.	1.2	0
25	BIOM-13. DNA METHYLATION MARKS GLUCOCORTICOID PATHWAY RESPONSE IN DEXAMETHASONE-TREATED BRAIN TUMOR PATIENTS. Neuro-Oncology, 2020, 22, ii4-ii4.	1.2	0
26	EPID-08. PRE-SURGERY IMMUNE PROFILES OF ADULT GLIOMA PATIENTS. Neuro-Oncology, 2020, 22, ii79-ii80.	1.2	0
27	SURG-15. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED DIFFUSE LOW-GRADE GLIOMA. Neuro-Oncology, 2020, 22, ii206-ii206.	1.2	0
28	EPCO-25. AN IMMUNOMETHYLOMIC PLATFORM INTEGRATING SYSTEMIC IMMUNE PROFILES AND EPIGENETIC AGE IN NEURO-ONCOLOGY. Neuro-Oncology, 2020, 22, ii74-ii74.	1.2	0
29	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii138-ii139.	1.2	0
30	NCOG-37. NATURAL LANGUAGE ASSESSMENT CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE IN ADULT GLIOMA PATIENTS. Neuro-Oncology, 2020, 22, ii137-ii137.	1.2	0
31	DDRE-10. IMMUNE PROFILES ASSOCIATE WITH OUTCOMES IN HLA-A*02:01+, H3.3K27M+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS TREATED WITH H3.3K27M PEPTIDE VACCINE COMBINED WITH POLY-ICLC: A PNOC REPORT. Neuro-Oncology, 2020, 22, ii63-ii63.	1.2	0
32	BIOM-38. PI3K/AKT/mTOR SIGNALING PATHWAY ACTIVITY IN IDH-MUTANT DIFFUSE GLIOMA. Neuro-Oncology, 2020, 22, ii9-ii10.	1.2	0
33	PATH-30. CLINICAL AND GENETIC CHARACTERISTICS OF HISTONE H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IN ADULTS. Neuro-Oncology, 2020, 22, ii170-ii171.	1.2	0
34	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2020, 22, ii40-ii40.	1.2	0
35	PATH-31. ARTIFICIAL INTELLIGENCE IN GLIOMA PATHOLOGY IMAGE ANALYSIS FOR RISK PREDICTION. Neuro-Oncology, 2020, 22, ii171-ii171.	1.2	0
36	SURG-07. DETECTION OF GLIOMA INFILTRATION AT THE TUMOR MARGIN USING QUANTITATIVE STIMULATED RAMAN SCATTERING MICROSCOPY. Neuro-Oncology, 2020, 22, ii204-ii204.	1.2	0

#	Article	IF	Citations
37	SURG-18. THE IMPACT OF NEUROLOGIC IMPAIRMENTS ON THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION IN NEWLY DIAGNOSED IDH-WILD TYPE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii207-ii207.	1.2	0